AstraZeneca investing in Macquarie Park

AstraZeneca has committed $200m to its Macquarie Park manufacturing facility.  The investment follows $100m announced in 2017 and will go towards increasing the facility’s production capabilities, creating 250 jobs and increasing exports to $4.4bn over the next four years.

Pascal Soriot, Chief Executive Officer, said:

“This investment will allow us to bring more life-changing respiratory medicines to patients, with asthma and chronic obstructive pulmonary disease.”

The local North Ryde facility is among the most digitised and innovative in the company’s global network, delivering medicines to millions of patients who need them in Australia, the Asia-Pacific region and other global markets.